What does Candel Therapeutics, Inc. do?
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is…
What is Candel Therapeutics, Inc.'s P/E and P/B ratio?
Candel Therapeutics, Inc. has a P/E ratio of -5.7 and a P/B ratio of 5.08.
What is Candel Therapeutics, Inc.'s debt-to-equity ratio?
Candel Therapeutics, Inc. has a debt-to-equity ratio of 0.39.
How much does Candel Therapeutics, Inc. owe compared with what it owns?
Candel Therapeutics, Inc. owes $0.39 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Candel Therapeutics, Inc.'s Positivity rank?
Candel Therapeutics, Inc. is ranked #4,973 of 6,774 companies globally and #2,621 of 4,000 in United States on PositoAI, with a Positivity Score of 18,653.
Does Candel Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Candel Therapeutics, Inc..
Where can I read the latest news about Candel Therapeutics, Inc.?
Recent headlines about Candel Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Candel Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Candel Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.